Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer

J Urol. 1993 Jul;150(1):126-31. doi: 10.1016/s0022-5347(17)35413-7.


Previous reports have shown that Her-2/neu oncogene expression in human breast cancer and ovarian cancer may be associated with poorer prognosis. We report the expression of Her-2/neu on fresh samples of known prostatic adenocarcinoma but not on those of benign prostatic hypertrophy. Using a monoclonal antibody (TA1) directed against human Her-2/neu oncogene product and an immunohistochemical staining method, no Her-2/neu expression was noted with benign prostatic hypertrophy (15 samples). With prostatic adenocarcinoma samples, a subset (9 of 25) showed overexpression of Her-2/neu. Such overexpression is correlated with higher histological grade, higher stage of disease, and high S phase and aneuploidy on flow cytometric analysis. These findings suggest that Her-2/neu may be a prognostic marker in prostate cancer as well.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / blood
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology*
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Male
  • Oncogene Proteins, Viral / analysis*
  • Prognosis
  • Prostate-Specific Antigen / blood
  • Prostatic Hyperplasia / genetics
  • Prostatic Hyperplasia / pathology
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology*
  • Receptor, ErbB-2


  • Oncogene Proteins, Viral
  • Receptor, ErbB-2
  • Prostate-Specific Antigen